The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components

Neurobiology of Disease

Volumn 18, Issue 1, 2005, Pages 176-183

  Farías, Ginny G ^a   Godoy, Juan A ^a   Vázquez, Mary C ^a   Adani, Rellie ^b   Meshulam, Haim ^b   Avila, Jesús ^c   Amitai, Gabi ^b   Inestrosa, Nibaldo C ^a  

^a Fac Cie Biol Pont Univ C   (Chile)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

A neurotoxicity; Alzheimer disease; Anti inflammatory ibuprofen; ChE inhibitor pyridostigmine; GSK 3 overexpression; Wnt signaling

Indexed keywords

1 [8 [2 (4 ISOBUTYLPHENYL)PROPIONYL]OCTYL] 3 N,N DIMETHYLCARBAMOYLPYRIDINIUM BROMIDE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA CATENIN; CHOLINESTERASE INHIBITOR; CYTOPLASM PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; IBUPROFEN; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINIUM DERIVATIVE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; ENZYME INHIBITION; HIPPOCAMPUS; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; BRAIN; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG COMPOUNDING; GLYCOGEN SYNTHASE KINASE 3; IBUPROFEN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PYRIDINIUM COMPOUNDS; PYRIDOSTIGMINE BROMIDE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS;

EID: 11844285723     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.09.012     Document Type: Article

References (46)

1. H. Aberle, A. Bauer, J. Stappert, A. Kispert, and R. Kemler β-Catenin is a target for the ubiquitin-proteasome pathway EMBO J. 16 1997 3797 3804
2. A. Alvarez, R. Alarcon, C. Opazo, E.O. Campos, F.J. Munoz, and F.H. Calderon Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils J. Neurosci. 18 1998 3213 3223
3. A. Alvarez, J.A. Godoy, K. Mullendorff, G.H. Olivares, M. Bronfman, and N.C. Inestrosa Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons Exp. Cell Res. 297 2004 186 196
4. G. Amitai, R. Adani, I. Rabinovitz, E. Beit-Yanai, E. Shohami, and G. Sod-Moriah Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for CNS disorders Proceedings of the International Symposium on Cholinergic Synapse-Function and Dysfunction, St. Moritz, Switzerland, May 2002 2004 Chap. 43
5. S.G. Anagnostaras, G.G. Murphy, S.E. Hamilton, S.L. Mitchell, N.P. Rahnama, and N.M. Nathanson Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice Nat. Neurosci. 6 2003 51 58
6. A. Cáceres, G. Banker, O. Steward, L. Binder, and M. Payne MAP2 is localized to the dendrites of hippocampal neurons which develop in culture Brain Res. 315 1984 314 318
7. A. Caricasole, A. Copani, A. Caruso, F. Caraci, L. Iacovelli, and M.A. Sortino The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol. Sci. 24 2003 233 238
8. M. Citron Strategies for disease modification in Alzheimer's disease Nat. Rev., Neurosci. 5 2004 677 685
9. M. Colombres, J.P. Sagal, and N.C. Inestrosa An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds Curr. Pharm. Des. 10 2004 3121 3130
10. G.V. De Ferrari, and N.C. Inestrosa Wnt signaling function in Alzheimer's disease Brain Res. Brain. Res. Rev. 33 2000 1 12
11. G.V. De Ferrari, M.A. Chacon, M.I. Barria, J.L. Garrido, J.A. Godoy, and G. Olivares Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils Mol. Psychiatry 8 2003 195 208
12. G.G. Farías, J.A. Godoy, F. Hernandez, J. Avila, A. Fisher, and N.C. Inestrosa M1 muscarinic receptor activation protects neurons from β-amyloid toxicity. A role for Wnt signalling pathway Neurobiol. Dis. 17 2004 337 348
13. R.A. Fuentealba, G. Farias, J. Scheu, M. Bronfman, M.P. Marzolo, and N.C. Inestrosa Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease Brain Res. Brain Res. Rev. 2004 (in press)
14. J.L. Garrido, J.A. Godoy, A. Alvarez, M. Bronfman, and N.C. Inestrosa Protein kinase C inhibits amyloid β peptide neurotoxicity by acting on members of the Wnt pathway FASEB J. 16 2002 1982 1984
15. C. Geula, and M.M. Mesulam Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease R.D. Terry R. Katzman K.L. Bick Alzheimer Disease 1994 Raven Press New York 263 291
16. E. Giacobini Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications Neurochem. Int. 32 1998 413 419
17. A.L. Guillozet, J.F. Smiley, D.C. Mash, and M.M. Mesulam Butyrylcholinesterase in the life cycle of amyloid plaques Ann. Neurol. 42 1997 909 918
18. C. Haass, and B. De Strooper The presenilins in Alzheimer's disease-proteolysis holds the key Science 286 1999 916 919
19. N.C. Inestrosa, A. Alvarez, C.A. Perez, R.D. Moreno, M. Vicente, and C. Linker Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme Neuron 16 1996 881 891
20. N.C. Inestrosa, S. Urra, and M. Colombres Acetylcholinesterase (AChE)-amyloid-β-peptide complexes in Alzheimer's disease. The Wnt signaling pathway Curr. Alzheimer's Res. 1 2004 1 6
21. B.A. Int' Veld, A. Ruitenberg, A. Hofman, L.J. Launer, C.M. van Duijn, and T. Stijnen Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease N. Engl. J. Med. 645 2001 1515 1521
22. D.K Lahiri, and M.R. Farlow Differential effect of tacrine and physostigmine on the secretion of the β-amyloid precursor protein in cell lines J. Mol. Neurosci. 7 1996 41 49
23. D.K. Lahiri, M.R. Farlow, N. Hintz, T. Utsuki, and N.H. Greig Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer disease Acta Neurol. Scand., Suppl. 176 2000 60 67
24. J.J. Lucas, F. Hernandez, P. Gomez-Ramos, M.A. Moran, R. Hen, and J. Avila Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice EMBO J. 20 2001 27 39
25. M.P. Mattson Pathways towards and away from Alzheimer's disease Nature 430 2004 631 639
26. R.T. Moon, B. Bowerman, M. Boutros, and N. Perrimon The promise and perils of Wnt signaling through β-catenin Science 296 2002 1644 1646
27. R.T. Moon, A.D Kohn, G.V. De Ferrari, and A. Kaykas Wnt and β-catenin signalling: disease and therapies Nat. Rev., Genet. 5 2004 689 699
28. F. Mori, C.C. Lai, F. Fusi, and E. Giacobini Cholinesterase inhibitors increase secretion of APPs in rat brain cortex NeuroReport 6 1995 633 636
29. 42 induction by NSAIDs R-enantiomers J. Neurochem. 83 2002 1009 1012
30. F.J. Muñoz, and N.C. Inestrosa Neurotoxicity of acetylcholinesterase-amyloid-β-peptide aggregates is dependent on the type of Aβ-peptide and the AChE concentration present in the complexes FEBS Lett. 450 1999 205 209
31. R.M. Nitsch, B.E. Slack, S.A. Farber, J.G. Schulz, M. Deng, and C. Kim Regulation of proteolytic processing of the amyloid β-protein precursor of Alzheimer's disease in transfected cell lines and in brain slices J. Neural Transm., Suppl. 44 1994 21 27
32. A.M. Palmer Pharmacotherapy for Alzheimer's disease: progress and prospects Trends Pharmacol. Sci. 23 2002 426 433
33. A. Patapoutian, and L.F. Reichardt Roles of Wnt proteins in neural development and maintenance Curr. Opin. Neurobiol. 10 2000 392 399
34. E.K. Perry, C.J. Smith, J.A. Court, J.R. Bonham, M. Rodway, and J.R. Atack Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro Neurosci. Lett. 91 1988 211 216
35. C.J. Phiel, C.A. Wilson, V.M. Lee, and P.S. Klein GSK-3β regulates production of Alzheimer's disease amyloid-β peptides Nature 423 2003 435 439
36. A.E. Reyes, M.A. Chacon, M.C. Dinamarca, W. Cerpa, C. Morgan, and NC. Inestrosa Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus: effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss Am. J. Pathol. 164 2004 2163 2174
37. D.J. Selkoe The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease Trends Cell Biol. 8 1998 447 453
38. M. Shaw, P. Cohen, and D.R. Alessi Further evidence that the inhibition of glycogen synthase kinase-3β by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216 FEBS Lett. 416 1997 307 311
39. V. Stambolic, L. Ruel, and J.R. Woodgett Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells Curr. Biol. 6 1996 1664 1668
40. A.L. Svensson, and A. Nordberg Tacrine and donepezil attenuate the neurotoxic effect of A ((25-35) in rat PC12 cells NeuroReport 9 1998 1519 1522
41. 42 independently of cyclooxygenase activity Nature 414 2001 212 216
42. K. Willert, and R. Nusse β-Catenin: a key mediator of Wnt signalling Curr. Opin. Genet. Dev. 8 1998 95 102
43. X.Q. Xiao, R. Wang, and X.C. Tang Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury J. Neurosci. Res. 61 2000 564 569
44. B.A. Yanker Mechanism of neuronal degeneration in Alzheimer's disease Neuron 16 1996 921 932
45. Z. Zhang, H. Hartmann, V.M. Do, D. Abramowski, C. Sturchler-Pierrat, and M. Staufenbiel Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis Nature 395 1998 698 702
46. 42 by inhibiting Rho Science 302 2003 1215 1217